Search

Displaying results 901 - 910 of 5300 in total
  1. Drug

    Hydroxyproline

    go.drugbank.com/drugs/DB08847
    Approved

    Therapeutically, hydroxyproline is being studied as an an experimental medicine but is approved in France as a combination topical gel product called Cicactive for small, superficial wounds.

    Mixtures: Soo Rye Han Dabityun Jiyun Foundation 21, Soo Rye Han Dabityoon Jiyoon Foundation 23
  2. Drug

    Manganese cation

    go.drugbank.com/drugs/DB06757
    ApprovedInvestigationalNutraceutical

    [A263687, A263662] In humans, manganese regulates several physiological processes by acting as a cofactor for proteins [A263657, A263662, A263667] making it an essential metal for normal development and … [A263657] Manganese can be found in over-the-counter nutritional supplements and vitamins.[A263667] It is commonly used in total parenteral nutrition (TPN) therapy.

    Mixtures: Se-Tan PLUS, Ribotin-E
  3. Drug

    Sodium tartrate

    go.drugbank.com/drugs/DB13707
    ApprovedWithdrawn

    It acts as an emulsifier and pH control agent in food products [L2590]. … This compound is commonly used as an emulsifier in cheese/cheese spread products and is not to exceed 4% concentration, according to Health Canada regulations [L2594].

  4. Drug

    Daridorexant

    go.drugbank.com/drugs/DB15031
    ApprovedInvestigational

    Daridorexant was designed via an intensive drug discovery program to improve the potency and maximize the duration of action while minimizing next-morning residual activity. … Novel drugs that target orexin receptors gained increasing attention after discovering the role of orexin signalling pathway in wakefulness and [almorexant], an orexin receptor antagonist that improved

  5. Drug

    Cipaglucosidase alfa

    go.drugbank.com/drugs/DB16708
    ApprovedInvestigational

    Cipaglucosidase alfa (ATB200) is a novel recombinant human acid alpha-glucosidase (GAA) investigated for the treatment of patients with Pompe disease, a rare inherited metabolic disorder characterized by a deficiency in GAA. Other types ...

  6. Drug

    CD68-ET3-LV

    go.drugbank.com/drugs/DB32864
    Investigational

    CD68-ET3-LV is an autologous gene therapy consisting of CD34+ hematopoietic stem and progenitor cells transduced ex-vivo with the CD68-ET3-LV lentiviral vector.

  7. Drug

    Inotuzumab ozogamicin

    go.drugbank.com/drugs/DB05889
    ApprovedInvestigational

    Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin … [A20352] Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

  8. Drug

    LS11

    go.drugbank.com/drugs/DB05918
    Investigational

    LS11(talaporfin sodium) is an agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity. … After intratumoral activation by light emitting diodes, taporfin sodium forms an extended high energy conformational state that generates singlet oxygen, resulting in free radical-mediated cell death.

  9. Drug

    Aluminum zirconium tetrachlorohydrex gly

    go.drugbank.com/drugs/DB11149
    ApprovedWithdrawn

    Aluminum zirconium tetrachlorohydrex gly is a common active ingredient in personal care products as an antiperspirant agent.

    Mixtures: Ban Ultra Antiperspirant Roll-ONProducts: Ban Clear Gel, Ban Clear Ap Roll-ON
  10. Drug

    Chlorzoxazone

    go.drugbank.com/drugs/DB00356
    Approved

    It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)